Associate Professor of Pediatrics, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Assistant Professor of Pediatrics, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Pediatric Allergy-immunology, Mashhad University of Medical Science, Mashhad, Iran.
Nuclear medicine Specialist, Nuclear medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Pediatrician, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
pneumonia are considered as the most important infection-induced cause of child mortality in developing countries over recent years. The aim of this study is to investigate the effect of prescribing zinc sulfate on improving the clinical symptoms of pneumonia in 2-59-month-old children.
This double-blind clinical trial study was performed on 108 children aged 2-59 months old with pneumonia admitted at Imam Reaz.Ghaem and Dr.Sheikh educational hospitals in Mashhad,Iran.Diagnosis of pneumonia was proven based on clinical examination and through chest x-ray. The patients were randomly assigned into control (n=54) and intervention (n=54). In the control group placebo was prescribed, while the intervention group received oral zinc sulfate during the hospitalization. The standard therapeutic protocol for treating pneumonia was implemented for both groups. During hospitalization, every 12 hours the clinical symptoms of both groups including tachypnea,fever, cough, intercostal retraction, hypoxia, crackles-wheezing, and finally duration of hospitalization were recorded. At admission and discharge, two blood samples were taken to determine the serum level of zinc.
Results: A total of 108 children participated in this study. The mean age in the intervention and control groups was 13.56+0.736 and 11.97+0.712 months, respectively (p>0.05). The findings indicated that the serum level of zinc sulfate after the intervention increased significantly in the intervention group (p<0.001).Clinical features had not any significant differences in 2 groups(p>0.05)except fever and and tachypnea in which in control group after 36 hours post hospitalization,tachypnea improvement and defervescence acute with significantly differences in controls(p 0.02) and (0.01) respectively
The results of this study indicated that zinc supplement did not have an effect on the duration of hospitalization of patients with pneumonia and also no improvement in clinical symptoms was observed compared to the placebo group.